These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 29452859)

  • 21. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer.
    Lee SE; Park HY; Hwang DY; Han HS
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene mutation and surgical technique: Suggestion or more?
    Kawaguchi Y; Lillemoe HA; Vauthey JN
    Surg Oncol; 2020 Jun; 33():210-215. PubMed ID: 31351766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
    Brannon AR; Vakiani E; Sylvester BE; Scott SN; McDermott G; Shah RH; Kania K; Viale A; Oschwald DM; Vacic V; Emde AK; Cercek A; Yaeger R; Kemeny NE; Saltz LB; Shia J; D'Angelica MI; Weiser MR; Solit DB; Berger MF
    Genome Biol; 2014 Aug; 15(8):454. PubMed ID: 25164765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
    Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability.
    Jan YH; Lu CT; Lam AK
    Hum Pathol; 2024 Jul; 149():21-28. PubMed ID: 38862093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
    Kleist B; Meurer T; Poetsch M
    Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
    Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
    Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.
    Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
    Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
    [No Abstract]   [Full Text] [Related]  

  • 38. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
    Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
    BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.